Foundayo vs GLP-1 Injections: What Is the Difference?

What Are the Main Differences Between Foundayo Pills and GLP-1 Injections?

Foundayo, Wegovy, and Mounjaro belong to the glucagon-like peptide-1 (GLP-1) group of medicines. Foundayo (orforglipron) is a once-daily tablet approved for weight loss in the US in April 2026. Wegovy (semaglutide) and Mounjaro (tirzepatide) are once-weekly injections given as a pre-filled pen under the skin. 

All three act on GLP-1 receptors. Foundayo is a partial agonist at the GLP-1 receptor, while Wegovy and Mounjaro are full agonists. They reduce appetite and slow stomach emptying to keep you full. Mounjaro has dual action and targets a second gut hormone called GIP. This also helps regulate appetite and blood sugar levels.

Wegovy and Mounjaro are peptide-based medicines, built from small proteins. Stomach acid breaks proteins down. Until now, all GLP-1 medicines have been injected to bypass the stomach. 

The new pill form of Wegovy has a special coating and strict dosing rules to protect the medicine from being broken down. To work, it needs an empty stomach and less than 120mL of water. Then wait at least 30 minutes before eating, drinking or taking other medicines.

Foundayo works differently. As a non-peptide, small-molecule drug, what Foundayo is comes down to its chemistry. 

Your stomach does not break it down. No fasting. No waiting. Much more convenient.

The US Food and Drug Administration (FDA) approved Foundayo as a weight loss treatment on 1 April 2026. Eli Lilly has submitted orforglipron to the Medicines and Healthcare products Regulatory Agency (MHRA) for UK review. A decision is expected in late 2026 or 2027.

Wegovy and Mounjaro have been prescribed for several years. Prescribers have long-term, real-world data on their performance and side effects. Foundayo is new. Evidence will take time to build. 

The main Foundayo pill vs injection difference: Foundayo has no food restrictions and no needles. For people who find self-injecting difficult, a daily pill removes that barrier.

Is Foundayo as Effective as Injectable GLP-1s for Weight Loss?

At the highest dose of Foundayo, studies show around 11% average weight loss over 72 weeks. Injectable Wegovy and Mounjaro produce higher figures in trials. But no study has tested Foundayo vs GLP-1 injection options directly. The figures below come from separate trials with different groups of people, so a direct comparison has limits.

	Foundayo	Wegovy	Mounjaro
Format	Daily pill	Weekly injection	Weekly injection
Average weight loss	11 – 12.4%	About 15%	About 21%
In real terms (100 kg person)	Roughly 11 kg	Roughly 15 kg	Roughly 21 kg
Trial length	72 weeks	68 weeks	72 weeks
Trial	ATTAIN-1	STEP 1	SURMOUNT-1

Results varied across participants. Trial averages reflect a range of starting weights, doses, and individual responses.

Mounjaro targets two gut hormones (GLP-1 and GIP) rather than one, which likely contributes to the larger weight loss seen in trials. The Foundayo vs Wegovy injection comparison is closer on numbers. Each weight loss injectable works differently, so your results may not match the trial average.

Is Foundayo better than injection options based on numbers?

No. The current trial date for Foundayo vs GLP-1 injections does not match injectable GLP-1s on average weight loss in current trial data. But for some people, a daily pill they can stick with may produce better real-world results than a weekly injection they stop taking. The Foundayo (orforglipron) vs injection choice comes down to which treatment you’ll actually be consistent with.

Which Is More Convenient to Take?

Foundayo is a tablet you take once a day, at any time of day, with or without food. No food restrictions and no meal planning around dosing. You don’t need to carry refrigerated injection pens when you travel. If you already take daily pills, adding Foundayo fits straight into your existing routine.

Wegovy and Mounjaro injections work on a different schedule. One injection per week, same day each week. They both come as pre-filled pens, used with a small needle. The injection process takes seconds.

Both Wegovy and Mounjaro need refrigeration before first use. You can keep Wegovy at room temperature for up to 6 weeks and Mounjaro for up to 30 days once opened. A weekly injectable suits people who prefer not to think about medication every day.

The oral weight loss pill vs jab decision comes down to your routine and comfort with needles. Some people find the idea of self-injecting difficult to get past, even with a small needle. A daily pill removes that worry entirely.

What matters most is finding a treatment you can stick with. Our team can help you work out which format fits your routine and medical history.

Which Has Fewer Side Effects?

All GLP-1 medicines affect the gut directly. That is why nausea, vomiting, constipation, and diarrhoea are the most common side effects of Foundayo, Wegovy, and Mounjaro. The side-effect profile is similar whether you take a weight loss pill vs injection.

Gut-related side effects with Foundayo tend to appear during dose increases. They usually settle within a few weeks. Around 60% to 70% of people were affected in the trial. 

Most symptoms were mild or moderate. About 37% of people on placebo, a version of the pill with no active ingredient, reported them too. This means the medication itself does not cause all the symptoms.

Symptoms settle as the body adjusts to treatment for the majority. Only 5-10% people stopped taking Foundayo during the trial because of side effects. Mostly at higher doses.

The one clear side-effect advantage of a weight loss pill over weekly injectables: no injection-site reactions. Redness, swelling, or itching where you have injected Wegovy and Mounjaro. These are usually minor and short-lived. Rotating the injection site each week helps to prevent these symptoms.

All GLP-1 drugs carry warnings about more serious but rare risks. Foundayo, Wegovy, and Mounjaro can all cause inflammation of the pancreas (pancreatitis) and gallbladder problems. 

They can also cause low blood sugar if combined with certain diabetes medicines. If you take medication for diabetes, let your GP or diabetic clinic know before starting a GLP-1. They can adjust your doses if needed.

Foundayo also carries a boxed warning about thyroid tumours found in animal studies. Other GLP-1 medicines carry the same warning. The risk has not been seen in humans. Foundayo is unsuitable if you or a close family member have had medullary thyroid cancer or a condition called multiple endocrine neoplasia type 2 (MEN 2).

If nausea or other symptoms get worse instead of settling, let our clinical team know. We can adjust your dose or slow down the increase. Moving to higher doses too quickly is one of the most common reasons side effects persist.

When Should I See a Doctor?

Contact your GP or call NHS 111 if you experience any of the following while taking any pill or injection for weight loss:

• Nausea, vomiting, or diarrhoea lasting several days that stops you from eating or drinking normally. Dehydration is the main risk, which can lead to kidney problems.
• Dark urine, dizziness when standing, dry mouth, or feeling faint. These all point to dehydration.
• Yellow skin or eyes. Get this checked promptly. It could be a gallbladder problem.
• A lump or swelling in your neck, hoarseness, or difficulty swallowing. These symptoms need checking for thyroid changes.

Call 999 or go to A&E if you have stomach pain that doesn’t go away, with or without vomiting. This can be a sign of pancreatitis and needs urgent assessment. The same if you notice signs of a severe allergic reaction. These are swelling of your face, lips, tongue, or throat, difficulty breathing, or a rapid heartbeat.

If you miss a dose of Foundayo, take it as soon as you remember on the same day. Do not take two tablets in one day. If you have missed seven or more days in a row, contact our team before restarting your treatment.

Key Takeaways

• Foundayo (orforglipron) is a once-daily weight loss pill with no food or water restrictions. US-approved in April 2026. Not yet licensed in the UK.
• Injectable GLP-1s produce more weight loss in trials. The GLP-1 pill vs injection gap is roughly 11% vs 15–21% at the highest doses.
• Common side effects are similar across all GLP-1 weight loss medications. Nausea, vomiting, diarrhoea, and constipation are all common, mostly during dose increases. No injection-site reactions with Foundayo.
• The oral GLP-1 vs injection choice comes down to your routine and comfort with needles. Our team can help you work out which format fits.

References

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1), New England Journal of Medicine, 2025 [Accessed 30 April 2026].

Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1), New England Journal of Medicine, 2021 [Accessed 30 April 2026].

Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), New England Journal of Medicine, 2022 [Accessed 30 April 2026].

FDA Approves First New Molecular Entity Under National Priority Voucher Program, US Food and Drug Administration, April 2026 [Accessed 30 April 2026].

Foundayo (orforglipron) Full Prescribing Information, Eli Lilly, 2026 [Accessed 30 April 2026].

Wegovy 2.4 mg FlexTouch, Summary of Product Characteristics, electronic Medicines Compendium (eMC) [Accessed 30 April 2026].

Mounjaro KwikPen, Summary of Product Characteristics, electronic Medicines Compendium (eMC) [Accessed 30 April 2026].

Authorship